Advancing Therapeutics for Ischemia Reperfusion
At Young Therapeutics, we are dedicated to pioneering research and development aimed at preventing ischemia reperfusion injury. Our groundbreaking work in experimental data demonstrates our commitment to improving cardiac and kidney functions post-injury.
About Young Therapeutics
Young Therapeutics is a biotech company focused on the prevention of Ischemia Reperfusion injury.<br/>Our experimental ex vivo and in vivo data (pig) to date have primarily concentrated on diminishing myocardial damage and sustaining cardiac function post-heart attack.<br/>Furthermore, we possess in vivo experimental evidence illustrating the preservation of glomerular filtration rate and the minimization of serum creatinine levels following ischemic and reperfusion events in mouse kidneys.<br/>Our molecules are applicable in various settings of ischemia reperfusion, encompassing heart attacks, organ transplants, acute kidney injury, and strokes.
$4million in SBIR research Grants
20+ publications
Cardiac Research
Groundbreaking studies demonstrate significant reductions in myocardial damage and improvements in cardiac function post-heart attack using our innovative therapeutics.
Kidney Preservation Studies
In vivo data shows promising results for glomerular filtration rate maintenance, particularly in acute kidney injury scenarios.
Broad Spectrum Applications
Our molecules have shown potential in treating a variety of ischemia reperfusion contexts, including organ transplants and stroke.
©Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.